The findings suggest that enfortumab vedotin, especially combined with pembrolizumab, offers promising beneficial outcomes in metastatic urothelial carcinoma treatment,” researchers wrote.

Taxane chemotherapy is unable to sensitize prostate cancer to immune checkpoint inhibitors, resulting in another negative trial with immunotherapy in prostate cancer,” said Andrea Necchi, MD.

A phase II trial shows that pembrolizumab and bevacizumab yield a 54.1% intracranial response rate and a median overall ...

Updated data "reinforce enfortumab vedotin and pembrolizumab as the new standard of care in frontline urothelial cancer,” said Thomas Powles, MD, MBBS.

PDS Biotechnology has commenced the randomised, multi-centre Phase III clinical trial, VERSATILE-003, to assess the efficacy ...

Werewolf Therapeutics, Inc. (the “Company” or “Werewolf”) (Nasdaq: HOWL), an innovative biopharmaceutical company pioneering the development of conditionally activated therapeutics engineered to ...

Full enrollment in cutaneous melanoma dose-expansion arms of Phase 1/1b clinical trial evaluating WTX-124 as monotherapy and in combination with pembrolizumab expected by the end of the first half ...

Mural Oncology (NASDAQ:MURA – Get Free Report)‘s stock had its “buy” rating restated by analysts at HC Wainwright in a research note issued to investors on Wednesday,Benzinga reports. They currently ...

Chronic cutaneous adverse events affected 8% of patients after checkpoint inhibitor therapy in a cohort study, often ...

Nadofaragene firadenovec intravesical gene therapy continues to show promise in treating BCG-unresponsive NMIBC bladder cancer.

NIH clinical trials are a lifeline for cancer patients like Baltimore native Vanessa, who received a groundbreaking immunotherapy treatment at the Kimmel Cancer Center ...

Burchfield, MD, and other participants discussed their experiences with the frontline combination regimens for advanced renal ...